Topical use of 5% acyclovir cream for the treatment of occult and verrucous equine sarcoids: a double-blinded placebo-controlled study.
- Controlled Clinical Trial
- Journal Article
Summary
The research article investigates the effectiveness of a 5% acyclovir cream in the treatment of equine sarcoids, a type of skin tumor in horses, in comparison to a placebo, ultimately finding no significant difference in results between the two treatments.
Research Objective and Methodology
The study’s primary objective was to determine the effectiveness of topical acyclovir cream for the treatment of equine sarcoids, a skin tumor found in horses. This particular study was double-blinded and placebo-controlled, ensuring a non-biased approach.
- Twenty-four equine sarcoids were treated with the 5% acyclovir cream, and twenty-five were treated with a placebo.
- These creams were applied topically twice a day for a period of six months.
- Before starting treatment and subsequently every month, photographs and swabs of the equine sarcoids were taken.
- The diameter and surface area of the sarcoid were measured and examined using the photographs, with the verrucosity (roughness or wart-like appearance) of the tumors quantified using a visual analog scale (VAS).
- The swabs taken were subjected to Polymerase Chain Reaction (PCR) to determine the presence of Bovine Papillomavirus (BPV) DNA, a virus linked to equine sarcoids.
Results of the Research
The findings of this thorough investigation did not yield definitive results supporting the efficacy of 5% acyclovir cream for the treatment of equine sarcoids.
- There were no significantly different success rates between the 5% acyclovir and placebo treatment groups, suggesting that the cream did not have a substantial effect on the sarcoids.
- The sarcoid’s diameter, surface area, and VAS score also did not show any significant difference or improvement after the treatment with acyclovir cream.
- In terms of BPV positivity rate, only after 1 month of treatment was a significantly higher rate found in the acyclovir-treated tumors as compared to the placebo-treated sarcoids; no significant difference was observed at other points in the timeline.
Conclusion of the Study
The study concludes that treatment with 5% acyclovir topical cream does not seem to yield better results for treating equine sarcoids than those obtained from a placebo treatment. Therefore, this suggests that acyclovir cream may not be a promising treatment approach for these equine skin tumors.
Cite This Article
Publication
Researcher Affiliations
- Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium. maarten.haspeslagh@ugent.be.
- Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium.
- Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium.
- Department of Surgery and Anaesthesiology of Domestic Animals, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium.
MeSH Terms
- Acyclovir / administration & dosage
- Acyclovir / therapeutic use
- Administration, Topical
- Animals
- Antineoplastic Agents / administration & dosage
- Antineoplastic Agents / therapeutic use
- Antiviral Agents / administration & dosage
- Antiviral Agents / therapeutic use
- Double-Blind Method
- Horse Diseases / drug therapy
- Horses
- Placebos
- Skin Cream
- Skin Neoplasms / drug therapy
- Skin Neoplasms / veterinary
Conflict of Interest Statement
References
- Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.. Proc Natl Acad Sci U S A 1977 Dec;74(12):5716-20.
- Miller WH, Miller RL. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase.. J Biol Chem 1980 Aug 10;255(15):7204-7.
- Datta AK, Colby BM, Shaw JE, Pagano JS. Acyclovir inhibition of Epstein-Barr virus replication.. Proc Natl Acad Sci U S A 1980 Sep;77(9):5163-6.
- Nasir L, Campo MS. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids.. Vet Dermatol 2008 Oct;19(5):243-54.
- Stadler S, Kainzbauer C, Haralambus R, Brehm W, Hainisch E, Brandt S. Successful treatment of equine sarcoids by topical aciclovir application.. Vet Rec 2011 Feb 19;168(7):187.
- Haspeslagh M, Taevernier L, Maes AA, Vlaminck LE, De Spiegeleer B, Croubels SM, Martens AM. Topical distribution of acyclovir in normal equine skin and equine sarcoids: An in vitro study.. Res Vet Sci 2016 Jun;106:107-11.
- Baker CC, Howley PM. Differential promoter utilization by the bovine papillomavirus in transformed cells and productively infected wart tissues.. EMBO J 1987 Apr;6(4):1027-35.
- Haspeslagh M, Vlaminck LE, Martens AM. Treatment of sarcoids in equids: 230 cases (2008-2013).. J Am Vet Med Assoc 2016 Aug 1;249(3):311-8.
- Martens A, De Moor A, Ducatelle R. PCR detection of bovine papilloma virus DNA in superficial swabs and scrapings from equine sarcoids.. Vet J 2001 May;161(3):280-6.
- Bogaert L, Van Poucke M, De Baere C, Dewulf J, Peelman L, Ducatelle R, Gasthuys F, Martens A. Bovine papillomavirus load and mRNA expression, cell proliferation and p53 expression in four clinical types of equine sarcoid.. J Gen Virol 2007 Aug;88(Pt 8):2155-2161.
- Haralambus R, Burgstaller J, Klukowska-Rötzler J, Steinborn R, Buchinger S, Gerber V, Brandt S. Intralesional bovine papillomavirus DNA loads reflect severity of equine sarcoid disease.. Equine Vet J 2010 May;42(4):327-31.
- Quinn G. Skin tumours in the horse : clinical presentation and management.. In Pract 2003;25:476–483.
- Bergvall KE. Sarcoids.. Vet Clin North Am Equine Pract 2013 Dec;29(3):657-71.
- Knottenbelt D, Edwards S, Daniel E. Diagnosis and treatment of the equine sarcoid.. In Pract 1995;17:123–129.
- Bogaert L, Martens A, Depoorter P, Gasthuys F. equine sarcoids - part 1 : clinical presentation and epidemiology.. Vlaams Diergeneeskd. Tijdschr 2008;77:2–9.
Citations
This article has been cited 4 times.- Song Y, Day CM, Afinjuomo F, Tan JE, Page SW, Garg S. Advanced Strategies of Drug Delivery via Oral, Topical, and Parenteral Administration Routes: Where Do Equine Medications Stand?. Pharmaceutics 2023 Jan 4;15(1).
- Saba C, Eggleston R, Parks A, Peroni J, Sjoberg E, Rice S, Tyma J, Williams J, Grosenbaugh D, Leard AT. ALVAC-fIL2, a feline interleukin-2 immunomodulator, as a treatment for sarcoids in horses: A pilot study.. J Vet Intern Med 2022 May;36(3):1179-1184.
- Weber LA, Delarocque J, Feige K, Kietzmann M, Kalbitz J, Meißner J, Paschke R, Cavalleri JV. Effects of Topically Applied Betulinic Acid and NVX-207 on Melanocytic Tumors in 18 Horses.. Animals (Basel) 2021 Nov 13;11(11).
- Weber LA, Funtan A, Paschke R, Delarocque J, Kalbitz J, Meißner J, Feige K, Kietzmann M, Cavalleri JV. In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer.. PLoS One 2020;15(11):e0241448.